The role of combination antifungal therapy in the treatment of invasive aspergillosis: A systematic review

International Journal of Infectious Diseases

Volumn 16, Issue 2, 2012, Pages

  Garbati, Musa A ^a   Alasmari, Faisal A ^a,b   Al Tannir, Mohammad A ^a   Tleyjeh, Imad M ^a,b  

^a KING FAHAD MEDICAL CITY   (Saudi Arabia)

^b MAYO CLINIC   (United States)

Author keywords

Antifungal; Combination therapy; Invasive aspergillosis; Review

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; POLYENE; POSACONAZOLE; VORICONAZOLE;

CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMBINATION ANTIFUNGAL THERAPY; DRUG MEGADOSE; DRUG THERAPY; DRUG TOLERABILITY; EMBASE; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE ASPERGILLOSIS; LIPID COMPLEX; MEDLINE; MONOTHERAPY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; THERAPY EFFECT; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; COHORT STUDIES; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84856012205     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.10.004     Document Type: Review

References (41)

1. Kontoyianus D.P., Bodey G.P. Invasive aspergillosis in 2002: an update. Eur J Clin Microbial Infect Dis 2002, 21:61-72.
2. Marr K.A., Carter R.A., Boeckh M., Martin P., Corey L. Invasive aspergillosis in allogeneic stem cell transplantation recipients: changes in epidemiology and risk factors. Blood 2002, 100:4358-4366.
3. Lin S.J., Schranz J., Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001, 32:358-366.
4. Pfaffenbach B., Donhuijsen K., Pahnke J., Bug R., Adamek R.J., Wegener M., et al. Systemic fungal infections in hematologic neoplasms. An autopsy study of 1,053 patients. Med Klin 1994, 89:299-304.
5. Groll A.H., Shah P.M., Mentzel C., Schneider M., Just-Nuebling G., Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996, 33:23-32.
6. Bodey G., Bueltmann B., Duguid W., Gibbs D., Hanak H., Hotchi M., et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992, 11:99-109.
7. Rex J.H., Sobel J.D. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001, 32:1191-1200.
8. Edmond M.B., Wallace S.E., McClish D.K., Pfaller M.A., Jones R.N., Wenzel R.P. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999, 29:239-244.
9. Upton A., Kirby K.A., Carpenter P., Boeckh M., Marr K.A. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44:531-540.
10. Denning D.W. Invasive aspergillosis. Clin Infect Dis 1998, 26:781-803.
11. Stevens D.A., Kan V.L., Judson M.A., Morrison V.A., Dummer S., Denning D.W., et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000, 30:696-709.
12. Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J.R., Dupont B., et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000, 79:250-260.
13. Kontoyiannis D.P., Boktour M., Hanna H., Torres H.A., Hachem R., Raad I.I. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 2005, 103:2334-2337.
14. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
15. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-360.
16. Denning D.W., Marr K.A., Lau W.M., Facklam D.P., Ratanatharathorn V., Becker C., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53:337-349.
17. Steinbach W.J., Stevens D.A., Denning D.W. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003, 37(Suppl 3):S188-S224.
18. Kontoyiannis D.P., Hachem R., Lewis R.E., Rivero G.A., Torres H.A., Thornby J., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98:292-299.
19. Aliff T.B., Maslak P.G., Jurcic J.G., Heaney M.L., Cathcart K.N., Sepkowitz K.A., et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003, 97:1025-1032.
20. Marr K.A., Boeckh M., Carter R.A., Kim H.W., Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797-802.
21. Kirkpatrick W.R., Perea S., Coco B.J., Patterson T.F. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564-2568.
22. Petraitis V., Petraitiene R., Sarafandi A.A., Kelaher A.M., Lyman C.A., Casler H.E., et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003, 187:1834-1843.
23. Singh N., Limaye A.P., Forrest G., Safdar N., Muñoz P., Pursell K., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81:320-326.
24. Arikan S., Lozano-Chiu M., Paetznick V., Rex J. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46:245-247.
25. Perea S., Gonzalez G., Fothergill A.W., Kirkpatrick W.R., Rinaldi M.G., Patterson T.F. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrobial Agents Chemother 2002, 46:3039-3041.
26. Lum L., Turco T., Leone J. Combination therapy with caspofungin and amphotericin B lipid complex. Am J Health Syst Pharm 2002, 1:80-81.
27. Rubin M., Carroll K., Cahill B. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002, 34:1160.
28. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., Perfect J.R., Rex J.H. Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693-715.
29. Patterson T.F. Combination antifungal therapy. Pediatr Infect Dis J 2003, 22:555-556.
30. Kontoyiannis D.P., Lewis R.E., Sagar N., May G., Prince R.A., Rolston K.V. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob Agents Chemother 2000, 44:2915-2918.
31. Schaffner A., Böhler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993, 36:421-424.
32. Schaffner A., Frick P.G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985, 151:902-910.
33. Maertens J., Glasmacher A., Herbrecht R., Thiebaut A., Cordonnier C., Segal B.H., et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006, 107:2888-2897.
34. Ascioglu S., Rex J.H., de Pauw B., Bennett J.E., Bille J., Crokaert F., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7-14.
35. Mihu C.N., Kassis C., Ramos E.R., Jiang Y., Hachem R.Y., Raad I.I. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?. Cancer 2010, 116:5290-5296.
36. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
37. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Ontario: The Ottawa Hospital Research Institute. Available at: (accessed November 12, 2011). http://www.ohri.ca/programs/clinical_epidemiology/nosgen.doc.
38. Jüni P., Altman D.G., Egger M. Systematic reviews in health care. Assessing the quality of controlled clinical trials. BMJ 2001, 323:42-46.
39. Raad I.I., Hanna H.A., Boktour M., Jiang Y., Torres H.A., Afif C., et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008, 22:496-503.
40. Caillot D., Thiebaut A., Herbrecht R., de Botton S., Pigneux A., Bernard F., et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007, 110:2740-2746.
41. Popp A.I., White M.H., Quadri T., Walshe L., Armstrong D. Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis 1999, 3:157-160.